A new drug developed by Eli Lilly for the prevention of osteoporosis has been approved by the Food and Drug Administration. The drug, called Evista (raloxifene hydrochloride), will compete with Merck's Fosamax treatment, as well as estrogen-replacement
A new drug developed by Eli Lilly for the prevention of osteoporosis has been approved by the Food and Drug Administration. The drug, called Evista (raloxifene hydrochloride), will compete with Merck's Fosamax treatment, as well as estrogen-replacement therapies such as Premarin from American Home Products.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.